Department of Dermatology, Oregon Health and Science University, Portland, Oregon, USA,
Department of Dermatology, Oregon Health and Science University, Portland, Oregon, USA.
Dermatology. 2023;239(4):664-669. doi: 10.1159/000530519. Epub 2023 Apr 5.
Sweet syndrome (SS), the prototypical neutrophilic dermatosis, is characterized by abrupt onset of tender plaques and nodules, classically accompanied by fever and leukocytosis. While management mainly relies on systemic corticosteroids, inadequate response can be seen in some patients that necessitates exploring other treatment options. Early diagnosis of malignancy-associated SS (MA-SS) along with detection of concomitant malignancy is crucial for improving patients' outcomes. Data regarding various clinical manifestations, extracutaneous associations, treatment, and outcomes are poorly characterized in the literature. We aimed to review all published case reports and case series to portray clinical features of SS including extracutaneous manifestations. We also describe reported treatment options and their outcomes to draw attention toward unmet therapeutic needs in the management of SS. In addition, for clinical and practical purposes, we attempted to delineate the distinction between MA-SS and nonmalignant subtypes of SS.
Sweet 综合征(SS),一种典型的中性粒细胞皮肤病,以疼痛性斑块和结节的突然出现为特征,经典表现为发热和白细胞增多。虽然主要依靠全身皮质类固醇治疗,但一些患者的反应并不理想,需要探索其他治疗方法。早期诊断恶性相关 SS(MA-SS)并发现伴随的恶性肿瘤对改善患者的预后至关重要。文献中对 SS 的各种临床表现、皮肤外表现、治疗和结局的描述很差。我们旨在回顾所有已发表的病例报告和病例系列,以描述 SS 的临床特征,包括皮肤外表现。我们还描述了报告的治疗选择及其结果,以引起人们对 SS 管理中未满足的治疗需求的关注。此外,为了临床和实际目的,我们试图区分 MA-SS 和非恶性 SS 亚型。